Genmab A/S (GMAB.CO) Akcie Kurz
Genmab A/S Kurz
Za posledních 19 let vzrostly tržby Genmab A/S o 19,3 % ročně a dosáhly 592,57 Mil. USD. Zisk na akcii rostl o 17,7 % ročně za posledních 12 let. U Genmab A/S je čistá marže 25,9 % dolů oproti 34,9 % před několika lety. Konsenzuální 12měsíční cílová cena pro Genmab A/S je 346,68 USD, asi pod cenu o 7,6 %. Z 26 analytiků jich 16 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Genmab A/S
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Genmab A/S a analýza akcií
Nejčastější otázky týkající se akcie Genmab A/S
The business model of Genmab A/S, a Danish biotechnology company, focuses on the development and commercialization of novel antibody therapeutics for the treatment of cancer. Genmab A/S specializes in the creation of differentiated and innovative antibody products, which are based on its proprietary antibody technologies. The company collaborates with various partners to advance its products through preclinical and clinical development stages. Genmab A/S aims to meet the needs of patients by discovering and delivering breakthrough treatments that target specific antigens involved in the progression of different types of cancer.
Genmab A/S is primarily active in the biotechnology industry.
The main competitors of Genmab A/S in the market include global pharmaceutical companies such as Roche Holding AG, Johnson & Johnson, Bristol-Myers Squibb Company, and Novartis AG. These companies are prominent players in the biopharmaceutical industry, engaging in research, development, and commercialization of innovative therapies. With its focus on the development of antibody-based drugs to treat cancer and other diseases, Genmab faces stiff competition in this highly regulated and competitive market. However, Genmab has established a strong reputation and is well-positioned with its innovative pipeline and strategic collaborations in the industry.
Genmab A/S is a Danish biotechnology company founded in 1999. The company specializes in the development of antibody therapeutics for the treatment of cancer and other diseases. Genmab has a strong focus on innovation and leveraging its proprietary antibody technologies to create novel drugs. Over the years, Genmab has established strategic collaborations with several pharmaceutical companies to advance its drug candidates. Notably, Genmab achieved significant success with the launch of Darzalex, an antibody-based therapy approved for multiple myeloma. The company continues to explore and develop groundbreaking therapies, harnessing the power of antibodies to improve patient outcomes and quality of life.
Genmab A/S, a leading biotechnology company, has achieved several significant milestones. One of the notable accomplishments is the development and approval of Darzalex (daratumumab), a breakthrough therapy for multiple myeloma. Genmab also entered into groundbreaking collaborations with renowned pharmaceutical companies, securing licensing agreements for their proprietary technology platforms. Additionally, the company has garnered worldwide recognition for its robust pipeline of innovative antibody-based therapies, addressing various unmet medical needs. Furthermore, Genmab's commitment to scientific excellence and steadfast dedication to improving patients' lives have earned them numerous prestigious awards and accolades within the biopharmaceutical industry.
Genmab A/S, a leading biotechnology company, is primarily present in various countries and regions. As a globally recognized player in the pharmaceutical industry, Genmab A/S has an extensive presence. The company operates in key markets such as the United States, Europe, Asia, and the Middle East. With a strong international footprint, Genmab A/S actively engages in research, development, and commercialization of innovative antibody-based therapies. Its continued growth and success are fueled by collaborations, partnerships, and a commitment to advancing breakthrough treatments for patients worldwide.
Genmab A/S represents values of innovation, dedication, and patient focus. The company believes in developing innovative antibody treatments to improve the lives of patients suffering from cancer and other diseases. Genmab prioritizes scientific excellence, collaboration, and striving for the best patient outcomes. Their corporate philosophy revolves around pushing boundaries, challenging the status quo, and making a meaningful impact in the field of biotechnology. Genmab A/S aims to deliver outstanding value for patients, healthcare providers, and shareholders through their commitment to research, development, and commercialization of novel antibody-based therapies.
Analytici aktuálně stanovují průměrnou cílovou cenu 333,89 USD pro akcii Genmab A/S (medián: 346,68 USD), tedy -11,0 % vůči poslední ceně. Konsensus vychází z 26 hodnocení analytiků.
27 analytiků aktuálně hodnotí akcii Genmab A/S: 17 doporučuje koupit, 8 držet a 2 prodat. Pro rok 2026 analytici očekávají u Genmab A/S tržby 4,49 Mld. USD a zisk na akcii 11,03 USD.
Při aktuálním kurzu se akcie Genmab A/S obchoduje za 333,93 EUR (375,37 USD).
Akcie Genmab A/S (GMAB.CO) je kótována na 8 burzách, mimo jiné: London (0MGB.L), Frankfurt (GE9.F), München (GE9.MU), Düsseldorf (GE9.DU), Wien (GMAB.VI), Kopenhagen (GMAB.CO).
Genmab A/S is an internationally leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer. The company, founded in 1999, is headquartered in Copenhagen, Denmark. Genmab also has offices in the United States, the Netherlands, Luxembourg, Japan, and China. Genmab operates its business in two main divisions: Research and Development, and Commercialization and Sales. Genmab's Research and Development department focuses on the discovery, development, and testing of antibodies for the treatment of cancer. The company is dedicated to developing innovative therapies for various types of cancer, including blood cancer, solid tumors, and hematological malignancies. Genmab's flagship product is Darzalex® (daratumumab), a monoclonal antibody for the treatment of patients with multiple myeloma. Darzalex® is now approved in the United States and distributed worldwide. Genmab also has a range of other antibodies in various stages of development, including tisotumab vedotin for the treatment of cervical cancer and advanced urothelial cancer, and enapotamab vedotin for the treatment of patients with solid tumors. The company works closely with other pharmaceutical and biotech companies to advance its research and development activities. Genmab has partnerships with companies such as Janssen Biotech, Novartis Pharmaceuticals, and Seattle Genetics to jointly develop and commercialize innovative therapies. Genmab's Commercialization and Sales department is responsible for the marketing and distribution of Darzalex® and other products. The company collaborates with other pharmaceutical companies, distribution partners, and regulatory authorities to ensure that the products are available, approved in the relevant markets, and accessible to patients. Genmab's business model is based on the development and commercialization of innovative and effective cancer therapies that meet the needs of patients. The company is committed to investing continuously in research and development and expanding its product pipeline to bring more therapies to the market in the future. Additionally, Genmab works closely with other companies to expand its reach and activities and further strengthen the company. In summary, Genmab A/S is an innovative biopharmaceutical company specializing in the development and commercialization of cancer therapies. The company has a wide range of products and a strong presence in the global market. With a strong research and development department and a dedicated sales department, Genmab aims to continue expanding and developing innovative therapies to meet the needs of patients.
Tržby očekávané za Genmab A/S činí 4,49 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Genmab A/S činí 741,55 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Genmab A/S je aktuálně 34,05. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Genmab A/S.
Poměr ceny k tržbám (P/S) Genmab A/S je aktuálně 5,62. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Genmab A/S.
Score kvality pro Genmab A/S je 5/10.
ISIN Genmab A/S je DK0010272202. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Genmab A/S je 565131. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Genmab A/S je GMAB.CO. Symbol tickeru se používá k obchodování akcií Genmab A/S na burze.
Genmab A/S akcie
Genmab A/S Peer Group
Genmab A/S Ticker
Genmab A/S FIGI
Všechny fundamentální údaje o Genmab A/S v podrobné analýze
Naše analýzy akcií společnosti Genmab A/S zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Genmab A/S. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: